Research Topics
| Scott R PlotkinSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteriaScott R Plotkin
Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts
Am J Med Genet A 161:405-16. 2013..In the next 5 years, the authors expect that advances in basic research in the pathogenesis of schwannomatosis will lead toward clinical investigations of potential drug therapies. © 2013 Wiley Periodicals, Inc...
Clinical features of schwannomatosis: a retrospective analysis of 87 patientsVanessa L Merker
Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA
Oncologist 17:1317-22. 2012..These findings support a proactive surveillance plan to identify tumors by magnetic resonance imaging scan in order to optimize surgical treatment and to treat associated pain, anxiety, and depression...- Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patientsScott R Plotkin
Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston 02114, USA
Otol Neurotol 33:1046-52. 2012..The aim of this study was to report extended follow-up in a larger cohort of similarly treated patients... - Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosisScott R Plotkin
Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America
PLoS ONE 7:e35711. 2012..The aim of this study was to establish an international cohort of patients with quantified whole-body internal tumor burden and to correlate tumor burden with clinical features of disease... - Genomic profiling distinguishes familial multiple and sporadic multiple meningiomasYiping Shen
Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, 02114, USA
BMC Med Genomics 2:42. 2009.... - Hearing improvement after bevacizumab in patients with neurofibromatosis type 2Scott R Plotkin
Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
N Engl J Med 361:358-67. 2009..There is no medical treatment for such tumors... - Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patientsScott R Plotkin
Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
J Neurosurg Spine 14:543-7. 2011..The aim of this paper was to define the clinical characteristics of spinal ependymomas associated with neurofibromatosis Type 2 (NF2)... - Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patientsScott R Plotkin
Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, U S A
Otol Neurotol 31:1135-43. 2010..We sought to determine the activity of erlotinib for progressive vestibular schwannoma (VS) associated with neurofibromatosis 2 (NF2)... 
Brain metastasesApril F Eichler
Scott R Plotkin, MD, PhD Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
Curr Treat Options Neurol 10:308-14. 2008....- Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapyScott R Plotkin
Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
Nat Clin Pract Oncol 5:487-91. 2008..A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation... - Facial numbness in a man with inguinal and retroperitoneal massesScott R Plotkin
Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Nat Clin Pract Oncol 2:54-8; quiz 1 p following 58. 2005..Neurologic examination was significant for diminished sensation over the left face to pinprick, left-sided dysmetria, and mild lateral instability of the trunk while walking... - Treatment of relapsed central nervous system lymphoma with high-dose methotrexateScott R Plotkin
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 10:5643-6. 2004..The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma... - Update on primary central nervous system lymphomaScott R Plotkin
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Curr Opin Neurol 18:645-53. 2005..Numerous studies examining this disorder have been published in the past 2 years. This review will discuss recent advances in the understanding of the pathology, radiographic appearance, and treatment of this disorder... - Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomideElizabeth R Gerstner
Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
J Neurooncol 103:325-32. 2011..Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies... - Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumorsHon Kit Wong
Department of Radiation Oncology, Steele Laboratory, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Cancer Res 70:3483-93. 2010..This study shows that anti-VEGF therapy normalizes the vasculature of schwannoma xenografts in nude mice and successfully controls the tumor growth, probably by reestablishing a natural balance between VEGF and semaphorin 3 signaling... - Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannomaScott R Plotkin
Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
J Neurooncol 93:61-77. 2009..We encourage adoption of standardized endpoints early in the development of phase II trials for this population to facilitate comparison of results across trials of different agents... - NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growthMarianne F James
Center for Human Genetic Research, Massachusetts General Hospital, Richard B Simches Research Building, 185 Cambridge St, Boston, MA 02114, USA
Mol Cell Biol 29:4250-61. 2009.... - Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor
Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
J Clin Oncol 28:2817-23. 2010..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma... - Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type IIGordon J Harris
3D Imaging Service, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA
Neurosurgery 62:1314-9; discussion 1319-20. 2008..The current study evaluated the relative sensitivity of volumetric versus linear diameter measurement for assessing VS growth rate and progression... - Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR imagesWenli Cai
Department of Radiology, Massachusetts General Hospital, 25 New Chardon St, 400C, Boston, MA 02114, USA
Radiology 250:665-73. 2009.... - Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escapeEmmanuelle di Tomaso
Department of Radiation Oncology, Massachusetts General Hospital and Massachusetts Institute of Technology, Boston, Massachusetts 02114, USA
Cancer Res 71:19-28. 2011.... - Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosisJacob L Jaremko
Musculoskeletal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
Skeletal Radiol 41:917-23. 2012..To demonstrate incidental findings and scoliosis on whole-body MRI (WBMRI) in patients with neurofibromatosis type 1 and 2 (NF1 & NF2, respectively), and schwannomatosis... - The neurofibromatoses. Part 2: NF2 and schwannomatosisChristine Lu-Emerson
Department of Neurology, University of Washington, Seattle, WA, USA
Rev Neurol Dis 6:E81-6. 2009..Recently, germline alterations in the SMARCB1/INI1 gene have been implicated in both familial and sporadic forms of this disorder. Neurologists play an important role in the diagnosis and management of the neurofibromatoses... - Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based studyAnna R Terry
Neurosurgical Service, White 502, Massachusetts General Hospital, Boston, MA 02114, USA
Neuro Oncol 14:768-76. 2012..Additional research is needed to improve understanding of obstetric risk in these patients and to assist with treatment, counseling, and monitoring during delivery... - Expression of SMARCB1 (INI1) mutations in familial schwannomatosisMiriam J Smith
Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
Hum Mol Genet 21:5239-45. 2012.... - Value of PET in the assessment of patients with neurofibromatosis type 1Miriam A Bredella
Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Yawkey 6E, Boston, MA 02114, USA
AJR Am J Roentgenol 189:928-35. 2007..The objective of our study was to investigate the use of PET in the detection of malignant peripheral nerve sheath tumors (MPNSTs) in patients with neurofibromatosis type 1 (NF1)... - NeurofibromatosesErik J Uhlmann
Massachusetts General Hospital, Boston, MA, USA
Adv Exp Med Biol 724:266-77. 2012..In this chapter, the genetics, molecular mechanism of disease, as well as clinical features, diagnosis and treatment are discussed... - Primary nervous system lymphomaScott R Plotkin
Brain Tumor Center, Cox 315, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
Curr Treat Options Oncol 3:525-35. 2002..Given the rarity of this tumor, patients with PNSL should be referred to tertiary cancer centers where ongoing clinical trials are underway to identify the optimal treatment of PNSL... - Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approachAgnies M van Eeghen
Department of Neurology, The Carol and James Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital, Boston, MA, USA
Dev Med Child Neurol 55:146-53. 2013.... - Emotional functioning of patients with neurofibromatosis tumor suppressor syndromeDaphne L Wang
Department of Neurology and Cancer Center, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts, USA
Genet Med 14:977-82. 2012..g., hearing loss; pain), little research has examined emotional correlates of neurofibromatosis. The purpose of this study was to examine emotional functioning among adult patients with neurofibromatosis... - Chemotherapy: present and futureAnna R Terry
Department of Neurosurgery, Massachusetts General Hospital, White 502, 55 Fruit Street, Boston, MA 02114, USA
Otolaryngol Clin North Am 45:471-86, x. 2012..The article also defines and recommends the use of specific clinical end points in future drug trials, describes previous and current experience with anti-VEGF and anti-EGFR agents, and delineates areas of future research... - Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromesChristopher J Farrell
Department of Neurosurgery, White 502, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
Neurol Clin 25:925-46, viii. 2007.... - Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trialAreej El-Jawahri
Departments of Medicine, Neurology and Cancer Center, and Oncology, Massachusetts General Hospital, 50 Staniford St, 9th Floor, Boston, MA 02114, USA
J Clin Oncol 28:305-10. 2010..To determine whether the use of a goals-of-care video to supplement a verbal description can improve end-of-life decision making for patients with cancer... - Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growthMarianne F James
Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Richard B Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
Neurobiol Dis 29:278-92. 2008..Merlin suppression by RNAi in arachnoidal cells replicated merlin-deficient meningioma features, thus establishing these cell systems as disease-relevant models for studying NF2 tumorigenesis... - The Neurofibromatoses. Part 1: NF1Christine Lu-Emerson
Department of Neurology, University of Washington, Seattle, WA, USA
Rev Neurol Dis 6:E47-53. 2009..Current treatment of patients with NF1 remains primarily surgical. Genetic counseling is essential for adult patients because molecular diagnostic testing can minimize the risk of transmission to children... - Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1Gavin P Dunn
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
J Neurosurg 118:142-8. 2013..Here, the authors aim to examine what role the extent of resection and other covariates play in the long-term survival of patients with NF1 in the setting of MPNST... - Facial reanimation of patients with neurofibromatosis type 2Kalpesh T Vakharia
Department of Otology and Laryngology, Division of Facial Plastic and Reconstructive Surgery, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts 02114, USA
Neurosurgery 70:237-43. 2012..Historically, physicians have not attempted to treat facial paralysis in these patients... - Clinical reasoning: a case of multiple intracerebral hemorrhagesLinda C Wendell
Department of Neurology, Rhode Island Hospital/Brown University, Providence, RI, USA
Neurology 69:E30-4. 2007 - Peripheral and cranial nerve sheath tumorsMaciej M Mrugala
Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Curr Opin Neurol 18:604-10. 2005..Vestibular schwannomas, neurogenetic syndromes such as schwannomatosis and multiple isolated neurofibromas, and malignant peripheral nerve sheath tumors are covered in this review... - Ramsay Hunt syndrome in a patient with metastatic lung cancer to brainRoy N Alcalay
Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
J Neurooncol 86:55-6. 2008